Skip to Main Content
  • Login
  • Contact Us
  • Donate

NANETS

  • About
    • Mission
    • Board of Directors
    • NANETS Structure
    • Staff
    • Committees
    • Committee Descriptions
    • NANETS Presidents
    • Lifetime Achievement
    • Outstanding Service
    • History
    • Diversity Statement
    • NANETS Awards
  • Education
    • NETCast Podcast Series
    • Regional NET Education
    • Virtual Programming Series
    • 2026 NET Medical Symposium
    • Conference Archives
    • About NETs
    • NANETS Call for Topics Calendar
  • Research
    • Abstracts Library
    • Abstract Instructions
    • Research Grants
    • Grant Recipients
  • Guidelines
  • Resources
    • Grant Resources
    • NANETS Mentorship Program
    • Employment Postings
    • Clinical Trials
    • Member DirectoryMember Directory
    • NET Around the World
    • Patient Resources
    • Women in NETs
    • COVID-19 Resource Page
    • NANETS Collaboration Submission Form
    • Provider Resources
  • News
    • NET eNews
    • Media
    • Endocrine-Related CancerEndocrine-Related Cancer
    • Photo Gallery
  • Membership
    • Member Login
    • Member Benefits
    • Member Categories
    • Join NOW
    • Spread the Word
    • Code of Conduct
  • 2025

  • 2024

  • 2023

  • 2022

  • 2021

  • 2020

  • 2019

  • 2018

  • 2017

  • 2016

  • 2015

  • 2014

  • 2013

  • 2012

  • 2011

  • 2010

  • 2009

OT02 – Netter-1: First Pivotal Multicenter Phase III Study Evaluating 177 Lu-dotatate in Midgut Neuroendocrine Tumors

Published in 2014 Listed under OT

Download

Sierra

[O10] Skotte - Demystifying DIPNECH: Initial Findings from a New Longitudinal Patient Registry

Published in 2024 Listed under OT

Download

[O10] Sonbol - Germline Cancer Testing in Unselected Patients with Neuroendocrine Neoplasms: A Multi-center Prospective Study

Published in 2022 Listed under OT

Download

[O11] Laffan - Health-related quality of life issues in patients with non- metastatic neuroendocrine neoplasms persist after treatment

Published in 2024 Listed under OT

Download

[O11] Rose-Krasnor - Pheo Para Alliance Patient Centered Research on Challenges for Those with Pheochromocytoma and Paraganglioma

Published in 2022 Listed under OT

Download

[O12] Korleski - The diagnostic accuracy of vasoactive intestinal peptide (VIP) for VIPoma

Published in 2024 Listed under OT

Download

[O12] Trikalinos - An Appraisal of Findings from a Neuroendocrine Neoplasm (NEN) Tumor Board (TB): Is There Added Value or Is It Redundant?

Published in 2022 Listed under OT

Download

[O14] Grewal - Racial Inequities in Neuroendocrine Tumor Clinical Trial Enrollment in the United States

Published in 2024 Listed under OT

Download

[O15] Grewal - Characterization of the Genomic and Immune Landscapes of 88 Cases of Pheochromocytomas and Paragangliomas: Implications for Development of Targeted Therapeutics

Published in 2024 Listed under OT

Download

[O1] Das - Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis

Published in 2022 Listed under OT

Download

[O1] Hall - Hereditary Predisposition and Clinical Presentation of Patients with Pheochromocytomas and Paragangliomas: Insights from a Large Clinical Cohort

Published in 2024 Listed under OT

Download

[O2] Duncan - The Association Between Patient-Reported Symptom Burden and Urgent Healthcare Use in Patients Diagnosed with Neuroendocrine Tumors

Published in 2022 Listed under OT

Download

[O2] Estrada - Characterization of early-onset gastroenteropancreatic neuroendocrine neoplasms at UCSF

Published in 2024 Listed under OT

Download

[O3] Baskar - Racial Disparities in End-of-Life Care Among Patients with Neuroendocrine Tumors

Published in 2024 Listed under OT

Download

[O3] Moon - Germline Pathogenic Variants in Patients with High- Grade (G3) Metastatic Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Published in 2022 Listed under OT

Download

[O4] Alaklabi - Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response

Published in 2022 Listed under OT

Download

[O4] Gujarathi - MEN1/DAXX alterations are associated with improved overall survival and treatment response in patients with pancreatic neuroendocrine tumors

Published in 2024 Listed under OT

Download

[O5] Benard - Implementation of a Patient Advisor Program for Neuroendocrine Tumor Patients: Acceptability, Benefits and Potential Challenges

Published in 2022 Listed under OT

Download

[O5] Gujarathi - Peptide Receptor Radionuclide Therapy versus Capecitabine/ Temozolomide for the treatment of Metastatic Pancreatic Neuroendocrine Tumors

Published in 2024 Listed under OT

Download

[O6] Al-Toubah - Empowering Participation: Trends in APP/AHP Authorship and the Impact of Travel Grants in Neuroendocrine Tumor Research

Published in 2024 Listed under OT

Download

[O6] Ramirez - Frequency of Pulmonary Carcinoid Tumor Research Presented at Major International Neuroendocrine and Lung Cancer Scientific Meetings

Published in 2022 Listed under OT

Download

[O7] Fields - Elevated Cancer Testis Antigen Expression Corresponds to Immune Activation and Improved Survival in Small Bowel Neuroendocrine Tumors

Published in 2024 Listed under OT

Download

[O7] Hunter - Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumor Patients

Published in 2022 Listed under OT

Download

[O8] Moon - Variants of Uncertain Significance (VUS) are More Common in Non-Caucasian Patients with Neuroendocrine Neoplasms (NENs)

Published in 2022 Listed under OT

Download

[O8] Sahvan - From Neuroendocrine Neoplasms to Sarcomas: How Genetic Testing Reveals Diagnostic Pitfalls

Published in 2024 Listed under OT

Download

[O9] Kollu - Improving PET Scan Report Clarity Using Radiotracer Information: A Physician Survey

Published in 2024 Listed under OT

Download

[O9] Lou - Leveraging Transcriptomics to Grade Pancreatic Neuroendocrine Neoplasms(NENs) and Assess Molecular Alterations Associated with Somatostatin Receptor(SSTR) Subtype Expression

Published in 2022 Listed under OT

Download

NANETS

167 Madison Avenue, Suite 205, #646 | New York, NY 10016
(718) 283-4783 | staff@nanets.net

Member Login

Twitter Facebook LinkedIn
  • Privacy Policy
  • |
  • Site Map

Copyright ©2026 ADG. All Rights Reserved | Web Design & Development by ADG Creative, a division of ADG.
ADG is a certified Women Owned Business.